Nuvectis Pharma Inc(NVCT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.28 | Insider Own | 35.16% | Shs Outstand | 26.7M | Perf Week | -11.3% |
| Market Cap | 0.60B | Forward P/E | - | EPS next Y | -10.38% | Insider Trans | 0.55% | Shs Float | 21.2M | Perf Month | -10.57% |
| Enterprise Value | 0.58B | PEG | - | EPS next Q | -0.24 | Inst Own | 33.29% | Short Float | 11.34% | Perf Quarter | -19.33% |
| Income | -0.03B | P/S | - | EPS this Y | 20.96% | Inst Trans | 51.05% | Short Ratio | 11.79 | Perf Half Y | 116% |
| Sales | 0.00B | P/B | 53.97 | EPS next 5Y | 2.54% | ROA | -122.61% | Short Interest | 2.40M | Perf YTD | 143.18% |
| Book/sh | 0.34 | P/C | 27.05 | EPS past 3/5Y | 4.25% -340.28% | ROE | -233.3% | 52W High | -37.28% ($29.27) | Perf Year | 185.54% |
| Cash/sh | 0.68 | P/FCF | - | Sales past 3/5Y | - | ROIC | -333.35% | 52W Low | 230.81% ($5.55) | Perf 3Y | 117.54% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -13.52% | Gross Margin | - | Volatility(W/M) | 6.78% 7.34% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.45 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.68 | EPS Q/Q | -0.88% | Profit Margin | - | RSI (14) | 40.37 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.68 | Sales Q/Q | - | SMA20 | -7.14% ($19.77) | Beta | -0.24 | Target Price | $35.4 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/4 | SMA50 | -15.16% ($21.64) | Rel Volume | 0.95 | Prev Close | $18.44 |
| Employees | 13 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -14.5% - | SMA200 | 26.53% ($14.51) | Avg Volume(3M) | 0.20M | Price | $18.36 |
| IPO | 2022/2/4 | Option/Short | Yes/Yes | Trades | 2154 | Volume | 192,748 | Change | -0.43% |
🧬 This is a US clinical-stage biotech company developing targeted oncology drugs in the field of precision oncology. The company is researching oral small-molecule drug candidates that target hard-to-treat solid tumors with specific genetic mutations, making it a typical small-cap drug developer whose corporate value is heavily influenced by progress in clinical data.
Over the past 1 year, roughly in the middle
37% below its 1-year high.
Traded about as much as usual. That is 95% of its average volume.
NVCT has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth is moderate
Earnings are expected to grow by +21.0% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 3 years ago, your return today would be +117.5%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 33.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #204 of 594 in the industry
Based on market cap of $599M.
ZVRA#202 Zevra Therapeutics Inc $612M PER 11.1 
NGNE#203 Neurogene Inc $609M PER - NVCT#204 Nuvectis Pharma Inc $599M PER - 
ANL#205 Adlai Nortye Group Ltd ADR $599M PER - 
ACRS#206 Aclaris Therapeutics Inc $583M PER - 
FAQ
What kind of company is NVCT?
NVCT belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of NVCT?
The market cap of NVCT is approximately $599M, ranking 3,004 within its sector.
What is the 52-week high and low for NVCT?
NVCT has recorded a 52-week high of $29.27 and a low of $5.55.
